TY  - JOUR
T1  - PEritoneal tuberculosis after imatinib therapy
AU  - Senn L, Kovacsovics T, Tarr PE, Meylan P
Y1  - 2009/02/09
N1  - 10.1001/archinternmed.2008.581
JO  - Archives of Internal Medicine
SP  - 312
EP  - 316
VL  - 169
IS  - 3
N2  - 
Imatinib mesylate, a selective inhibitor of the BCR-ABL tyrosine kinase gene, is now a standard therapy in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). Recent studies have shown that imatinib alters T-cell–mediated immune responses,1- 4 raising the possibility of opportunistic infections associated with imatinib therapy. So far, few epidemiological data are available to support this hypothesis. We report herein a case of peritoneal tuberculosis (TB) following 4 months of imatinib therapy for CML.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2008.581
UR  - http://dx.doi.org/10.1001/archinternmed.2008.581
ER  -